GSK drops celi­ac drug, an­ti-bac­te­r­i­al vac­cine in lat­est pipeline sweep

On a con­tin­ued mis­sion to set a high bar for its R&D group — which now gears heav­i­ly to­ward vac­cines and spe­cial­ty med­i­cines — GSK has swept two pro­grams out of its ear­ly- to mid-stage pipeline.

GSK re­port­ed in its lat­est quar­ter­ly up­date that it’d delet­ed a com­pound dubbed GSK3915393 from its pipeline. The com­pound in­hibits an en­zyme known as trans­g­lu­t­a­m­i­nase 2, or TG2, and the com­pa­ny was pre­vi­ous­ly look­ing in­to its ap­pli­ca­tion in celi­ac dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER